MXPA03008403A - Combinaciones sinergisticas de ligandos del receptor retinoide y agentes citotoxicos seleccionados para tratamiento de cancer. - Google Patents

Combinaciones sinergisticas de ligandos del receptor retinoide y agentes citotoxicos seleccionados para tratamiento de cancer.

Info

Publication number
MXPA03008403A
MXPA03008403A MXPA03008403A MXPA03008403A MXPA03008403A MX PA03008403 A MXPA03008403 A MX PA03008403A MX PA03008403 A MXPA03008403 A MX PA03008403A MX PA03008403 A MXPA03008403 A MX PA03008403A MX PA03008403 A MXPA03008403 A MX PA03008403A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
cytotoxic agents
receptor ligands
retinoid receptor
Prior art date
Application number
MXPA03008403A
Other languages
English (en)
Inventor
Fred Christopher Zusi
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03008403A publication Critical patent/MXPA03008403A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MXPA03008403A 2001-03-22 2002-03-22 Combinaciones sinergisticas de ligandos del receptor retinoide y agentes citotoxicos seleccionados para tratamiento de cancer. MXPA03008403A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27775401P 2001-03-22 2001-03-22
PCT/US2002/008718 WO2002078620A2 (en) 2001-03-22 2002-03-22 Synergistic combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA03008403A true MXPA03008403A (es) 2004-01-29

Family

ID=23062213

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008403A MXPA03008403A (es) 2001-03-22 2002-03-22 Combinaciones sinergisticas de ligandos del receptor retinoide y agentes citotoxicos seleccionados para tratamiento de cancer.

Country Status (15)

Country Link
EP (1) EP1383491A2 (es)
JP (1) JP2004528316A (es)
KR (1) KR20030086314A (es)
CN (1) CN1498105A (es)
BR (1) BR0207681A (es)
CA (1) CA2441335A1 (es)
CZ (1) CZ20032540A3 (es)
DE (1) DE02733871T1 (es)
ES (1) ES2214985T1 (es)
HU (1) HUP0400255A2 (es)
IL (1) IL157358A0 (es)
MX (1) MXPA03008403A (es)
PL (1) PL368946A1 (es)
TR (1) TR200400812T3 (es)
WO (1) WO2002078620A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007108272A1 (ja) * 2006-03-23 2007-09-27 Tmrc Co., Ltd. 癌治療用キットおよび癌治療用医薬組成物

Also Published As

Publication number Publication date
KR20030086314A (ko) 2003-11-07
CN1498105A (zh) 2004-05-19
JP2004528316A (ja) 2004-09-16
BR0207681A (pt) 2004-07-27
WO2002078620A2 (en) 2002-10-10
EP1383491A2 (en) 2004-01-28
WO2002078620A3 (en) 2003-04-17
PL368946A1 (en) 2005-04-04
CA2441335A1 (en) 2002-10-10
DE02733871T1 (de) 2004-08-26
CZ20032540A3 (cs) 2004-05-12
HUP0400255A2 (hu) 2004-08-30
IL157358A0 (en) 2004-02-19
ES2214985T1 (es) 2004-10-01
TR200400812T3 (tr) 2004-07-21

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
HK1072443A1 (en) Immunoconjugates for the treatment of tumours
IL196301A0 (en) Medicament for the treatment of hapatitis c
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
HUP0400314A3 (en) Pharmaceutical combinations for the treatment of cancer
AU6147401A (en) Compositions and methods for the treatment of cancer
ZA200305126B (en) Methods of administering epothilone analogs for the treatment of cancer.
EP1311262A4 (en) COMBINED TREATMENT AGAINST CANCER
EP1535610A4 (en) THERAPEUTIC CANCER
IL159887A0 (en) Combination therapy for the treatment of cancer
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
HK1051692A1 (en) Quinolinyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain.
EP1349485A4 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF OVARIAL CARCINOMA
PL368035A1 (en) Compositions and methods for the treatment of cancer
AU3483001A (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AU2003284885A8 (en) Device and methods for sequential, regional delivery of multiple cytotoxic agents
MXPA03006412A (es) Metodos para administrar analogos de epotilona para tratamiento de cancer.
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
MXPA03008403A (es) Combinaciones sinergisticas de ligandos del receptor retinoide y agentes citotoxicos seleccionados para tratamiento de cancer.
GB0026015D0 (en) Cancer treatment
ZA200203166B (en) Treatment of cancer.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.